The global Non-injectable Insulin market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Non-injectable insulin refers to a class of medications used to treat diabetes that do not need to be administered by injection. These medications are usually given orally or by other non-injectable routes to help control blood sugar levels and reduce or delay the onset of diabetes-related complications.

People with diabetes rely on insulin to control their blood glucose levels. This drug regulates and controls blood glucose levels by injected subcutaneously. A report from 2022 indicated that diabetes drugs around the world generated revenue of $78 billion. Since insulin is the preferred drug of choice for most diabetics, nasal or oral insulin intake provides comfort as an effective alternative to all other diabetes drugs.

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Non-injectable Insulin market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Non-injectable Insulin Market Report

Report Metric	Details
Report Name	Non-injectable Insulin Market
Segment by Type	Oral Pills Sprays Others
Segment by Application	T1DM T2DM
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novo Nordisk, Sanofi, Eli Lilly, MannKind Corporation, Biocon, Janssen Pharmaceuticals, Adocia, Oramed Pharmaceuticals, Aerami Therapeutics, Medtronic, Verily Life Sciences, Larimar Therapeutics, Senseonics, Bigfoot Biomedical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Non-injectable Insulin study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Non-injectable Insulin Market report?

Ans: The main players in the Non-injectable Insulin Market are Novo Nordisk, Sanofi, Eli Lilly, MannKind Corporation, Biocon, Janssen Pharmaceuticals, Adocia, Oramed Pharmaceuticals, Aerami Therapeutics, Medtronic, Verily Life Sciences, Larimar Therapeutics, Senseonics, Bigfoot Biomedical

What are the Application segmentation covered in the Non-injectable Insulin Market report?

Ans: The Applications covered in the Non-injectable Insulin Market report are T1DM, T2DM

What are the Type segmentation covered in the Non-injectable Insulin Market report?

Ans: The Types covered in the Non-injectable Insulin Market report are Oral Pills, Sprays, Others

1 Study Coverage

1.1 Introduction to Non-injectable Insulin: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Non-injectable Insulin Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Oral Pills

1.2.3 Sprays

1.2.4 Others

1.3 Market Segmentation by Application

1.3.1 Global Non-injectable Insulin Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 T1DM

1.3.3 T2DM

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Non-injectable Insulin Revenue Estimates and Forecasts 2020-2031

2.2 Global Non-injectable Insulin Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Non-injectable Insulin Sales Estimates and Forecasts 2020-2031

2.4 Global Non-injectable Insulin Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global Non-injectable Insulin Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global Non-injectable Insulin Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 Oral Pills Market Size by Manufacturers

3.5.2 Sprays Market Size by Manufacturers

3.5.3 Others Market Size by Manufacturers

3.6 Global Non-injectable Insulin Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Non-injectable Insulin Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global Non-injectable Insulin Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Non-injectable Insulin Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global Non-injectable Insulin Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America Non-injectable Insulin Sales and Revenue by Type (2020-2031)

6.4 North America Non-injectable Insulin Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Non-injectable Insulin Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe Non-injectable Insulin Sales and Revenue by Type (2020-2031)

7.4 Europe Non-injectable Insulin Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Non-injectable Insulin Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific Non-injectable Insulin Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific Non-injectable Insulin Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific Non-injectable Insulin Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America Non-injectable Insulin Sales and Revenue by Type (2020-2031)

9.4 Central and South America Non-injectable Insulin Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Non-injectable Insulin Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa Non-injectable Insulin Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa Non-injectable Insulin Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Non-injectable Insulin Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Novo Nordisk

11.1.1 Novo Nordisk Corporation Information

11.1.2 Novo Nordisk Business Overview

11.1.3 Novo Nordisk Non-injectable Insulin Product Models, Descriptions and Specifications

11.1.4 Novo Nordisk Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Novo Nordisk Non-injectable Insulin Sales by Product in 2024

11.1.6 Novo Nordisk Non-injectable Insulin Sales by Application in 2024

11.1.7 Novo Nordisk Non-injectable Insulin Sales by Geographic Area in 2024

11.1.8 Novo Nordisk Non-injectable Insulin SWOT Analysis

11.1.9 Novo Nordisk Recent Developments

11.2 Sanofi

11.2.1 Sanofi Corporation Information

11.2.2 Sanofi Business Overview

11.2.3 Sanofi Non-injectable Insulin Product Models, Descriptions and Specifications

11.2.4 Sanofi Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 Sanofi Non-injectable Insulin Sales by Product in 2024

11.2.6 Sanofi Non-injectable Insulin Sales by Application in 2024

11.2.7 Sanofi Non-injectable Insulin Sales by Geographic Area in 2024

11.2.8 Sanofi Non-injectable Insulin SWOT Analysis

11.2.9 Sanofi Recent Developments

11.3 Eli Lilly

11.3.1 Eli Lilly Corporation Information

11.3.2 Eli Lilly Business Overview

11.3.3 Eli Lilly Non-injectable Insulin Product Models, Descriptions and Specifications

11.3.4 Eli Lilly Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 Eli Lilly Non-injectable Insulin Sales by Product in 2024

11.3.6 Eli Lilly Non-injectable Insulin Sales by Application in 2024

11.3.7 Eli Lilly Non-injectable Insulin Sales by Geographic Area in 2024

11.3.8 Eli Lilly Non-injectable Insulin SWOT Analysis

11.3.9 Eli Lilly Recent Developments

11.4 MannKind Corporation

11.4.1 MannKind Corporation Corporation Information

11.4.2 MannKind Corporation Business Overview

11.4.3 MannKind Corporation Non-injectable Insulin Product Models, Descriptions and Specifications

11.4.4 MannKind Corporation Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 MannKind Corporation Non-injectable Insulin Sales by Product in 2024

11.4.6 MannKind Corporation Non-injectable Insulin Sales by Application in 2024

11.4.7 MannKind Corporation Non-injectable Insulin Sales by Geographic Area in 2024

11.4.8 MannKind Corporation Non-injectable Insulin SWOT Analysis

11.4.9 MannKind Corporation Recent Developments

11.5 Biocon

11.5.1 Biocon Corporation Information

11.5.2 Biocon Business Overview

11.5.3 Biocon Non-injectable Insulin Product Models, Descriptions and Specifications

11.5.4 Biocon Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 Biocon Non-injectable Insulin Sales by Product in 2024

11.5.6 Biocon Non-injectable Insulin Sales by Application in 2024

11.5.7 Biocon Non-injectable Insulin Sales by Geographic Area in 2024

11.5.8 Biocon Non-injectable Insulin SWOT Analysis

11.5.9 Biocon Recent Developments

11.6 Janssen Pharmaceuticals

11.6.1 Janssen Pharmaceuticals Corporation Information

11.6.2 Janssen Pharmaceuticals Business Overview

11.6.3 Janssen Pharmaceuticals Non-injectable Insulin Product Models, Descriptions and Specifications

11.6.4 Janssen Pharmaceuticals Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 Janssen Pharmaceuticals Recent Developments

11.7 Adocia

11.7.1 Adocia Corporation Information

11.7.2 Adocia Business Overview

11.7.3 Adocia Non-injectable Insulin Product Models, Descriptions and Specifications

11.7.4 Adocia Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 Adocia Recent Developments

11.8 Oramed Pharmaceuticals

11.8.1 Oramed Pharmaceuticals Corporation Information

11.8.2 Oramed Pharmaceuticals Business Overview

11.8.3 Oramed Pharmaceuticals Non-injectable Insulin Product Models, Descriptions and Specifications

11.8.4 Oramed Pharmaceuticals Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.8.5 Oramed Pharmaceuticals Recent Developments

11.9 Aerami Therapeutics

11.9.1 Aerami Therapeutics Corporation Information

11.9.2 Aerami Therapeutics Business Overview

11.9.3 Aerami Therapeutics Non-injectable Insulin Product Models, Descriptions and Specifications

11.9.4 Aerami Therapeutics Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.9.5 Aerami Therapeutics Recent Developments

11.10 Medtronic

11.10.1 Medtronic Corporation Information

11.10.2 Medtronic Business Overview

11.10.3 Medtronic Non-injectable Insulin Product Models, Descriptions and Specifications

11.10.4 Medtronic Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.10.5 Medtronic Recent Developments

11.11 Verily Life Sciences

11.11.1 Verily Life Sciences Corporation Information

11.11.2 Verily Life Sciences Business Overview

11.11.3 Verily Life Sciences Non-injectable Insulin Product Models, Descriptions and Specifications

11.11.4 Verily Life Sciences Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.11.5 Verily Life Sciences Recent Developments

11.12 Larimar Therapeutics

11.12.1 Larimar Therapeutics Corporation Information

11.12.2 Larimar Therapeutics Business Overview

11.12.3 Larimar Therapeutics Non-injectable Insulin Product Models, Descriptions and Specifications

11.12.4 Larimar Therapeutics Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.12.5 Larimar Therapeutics Recent Developments

11.13 Senseonics

11.13.1 Senseonics Corporation Information

11.13.2 Senseonics Business Overview

11.13.3 Senseonics Non-injectable Insulin Product Models, Descriptions and Specifications

11.13.4 Senseonics Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.13.5 Senseonics Recent Developments

11.14 Bigfoot Biomedical

11.14.1 Bigfoot Biomedical Corporation Information

11.14.2 Bigfoot Biomedical Business Overview

11.14.3 Bigfoot Biomedical Non-injectable Insulin Product Models, Descriptions and Specifications

11.14.4 Bigfoot Biomedical Non-injectable Insulin Sales, Price, Revenue and Gross Margin (2020-2025)

11.14.5 Bigfoot Biomedical Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 Non-injectable Insulin Industry Chain

12.2 Non-injectable Insulin Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 Non-injectable Insulin Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 Non-injectable Insulin Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Non-injectable Insulin Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Non-injectable Insulin Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Janssen Pharmaceuticals

Adocia

Oramed Pharmaceuticals

List of Tables

Table 1. Global Non-injectable Insulin Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Non-injectable Insulin Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Non-injectable Insulin Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Non-injectable Insulin Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Non-injectable Insulin Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Non-injectable Insulin Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Units)

Table 7. Global Non-injectable Insulin Sales by Region (2020-2025) & (Units)

Table 8. Global Non-injectable Insulin Sales by Region (2026-2031) & (Units)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Non-injectable Insulin Sales by Manufacturers (2020-2025) & (Units)

Table 11. Global Non-injectable Insulin Sales Share by Manufacturers (2020-2025)

Table 12. Global Non-injectable Insulin Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global Non-injectable Insulin Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global Non-injectable Insulin by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-injectable Insulin as of 2024)

Table 16. Global Non-injectable Insulin Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global Non-injectable Insulin Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)

Table 18. Key Manufacturers Non-injectable Insulin Manufacturing Base and Headquarters

Table 19. Global Non-injectable Insulin Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global Non-injectable Insulin Sales by Type (2020-2025) & (Units)

Table 23. Global Non-injectable Insulin Sales by Type (2026-2031) & (Units)

Table 24. Global Non-injectable Insulin Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global Non-injectable Insulin Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global Non-injectable Insulin ASP by Type (2020-2031) & (US$/Unit)

Table 27. Technical Specifications by Key Product Type

Table 28. Global Non-injectable Insulin Sales by Application (2020-2025) & (Units)

Table 29. Global Non-injectable Insulin Sales by Application (2026-2031) & (Units)

Table 30. Non-injectable Insulin High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global Non-injectable Insulin Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global Non-injectable Insulin Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global Non-injectable Insulin ASP by Application (2020-2031) & (US$/Unit)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America Non-injectable Insulin Growth Accelerators and Market Barriers

Table 37. North America Non-injectable Insulin Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America Non-injectable Insulin Sales (Units) by Country (2020 VS 2024 VS 2031)

Table 39. Europe Non-injectable Insulin Growth Accelerators and Market Barriers

Table 40. Europe Non-injectable Insulin Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe Non-injectable Insulin Sales (Units) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific Non-injectable Insulin Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific Non-injectable Insulin Sales (Units) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific Non-injectable Insulin Growth Accelerators and Market Barriers

Table 45. Southeast Asia Non-injectable Insulin Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America Non-injectable Insulin Investment Opportunities and Key Challenges

Table 47. Central and South America Non-injectable Insulin Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa Non-injectable Insulin Investment Opportunities and Key Challenges

Table 49. Middle East and Africa Non-injectable Insulin Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Novo Nordisk Corporation Information

Table 51. Novo Nordisk Description and Major Businesses

Table 52. Novo Nordisk Product Models, Descriptions and Specifications

Table 53. Novo Nordisk Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 54. Novo Nordisk Sales Value Proportion by Product in 2024

Table 55. Novo Nordisk Sales Value Proportion by Application in 2024

Table 56. Novo Nordisk Sales Value Proportion by Geographic Area in 2024

Table 57. Novo Nordisk Non-injectable Insulin SWOT Analysis

Table 58. Novo Nordisk Recent Developments

Table 59. Sanofi Corporation Information

Table 60. Sanofi Description and Major Businesses

Table 61. Sanofi Product Models, Descriptions and Specifications

Table 62. Sanofi Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 63. Sanofi Sales Value Proportion by Product in 2024

Table 64. Sanofi Sales Value Proportion by Application in 2024

Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024

Table 66. Sanofi Non-injectable Insulin SWOT Analysis

Table 67. Sanofi Recent Developments

Table 68. Eli Lilly Corporation Information

Table 69. Eli Lilly Description and Major Businesses

Table 70. Eli Lilly Product Models, Descriptions and Specifications

Table 71. Eli Lilly Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 72. Eli Lilly Sales Value Proportion by Product in 2024

Table 73. Eli Lilly Sales Value Proportion by Application in 2024

Table 74. Eli Lilly Sales Value Proportion by Geographic Area in 2024

Table 75. Eli Lilly Non-injectable Insulin SWOT Analysis

Table 76. Eli Lilly Recent Developments

Table 77. MannKind Corporation Corporation Information

Table 78. MannKind Corporation Description and Major Businesses

Table 79. MannKind Corporation Product Models, Descriptions and Specifications

Table 80. MannKind Corporation Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 81. MannKind Corporation Sales Value Proportion by Product in 2024

Table 82. MannKind Corporation Sales Value Proportion by Application in 2024

Table 83. MannKind Corporation Sales Value Proportion by Geographic Area in 2024

Table 84. MannKind Corporation Non-injectable Insulin SWOT Analysis

Table 85. MannKind Corporation Recent Developments

Table 86. Biocon Corporation Information

Table 87. Biocon Description and Major Businesses

Table 88. Biocon Product Models, Descriptions and Specifications

Table 89. Biocon Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Biocon Sales Value Proportion by Product in 2024

Table 91. Biocon Sales Value Proportion by Application in 2024

Table 92. Biocon Sales Value Proportion by Geographic Area in 2024

Table 93. Biocon Non-injectable Insulin SWOT Analysis

Table 94. Biocon Recent Developments

Table 95. Janssen Pharmaceuticals Corporation Information

Table 96. Janssen Pharmaceuticals Description and Major Businesses

Table 97. Janssen Pharmaceuticals Product Models, Descriptions and Specifications

Table 98. Janssen Pharmaceuticals Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 99. Janssen Pharmaceuticals Recent Developments

Table 100. Adocia Corporation Information

Table 101. Adocia Description and Major Businesses

Table 102. Adocia Product Models, Descriptions and Specifications

Table 103. Adocia Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 104. Adocia Recent Developments

Table 105. Oramed Pharmaceuticals Corporation Information

Table 106. Oramed Pharmaceuticals Description and Major Businesses

Table 107. Oramed Pharmaceuticals Product Models, Descriptions and Specifications

Table 108. Oramed Pharmaceuticals Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 109. Oramed Pharmaceuticals Recent Developments

Table 110. Aerami Therapeutics Corporation Information

Table 111. Aerami Therapeutics Description and Major Businesses

Table 112. Aerami Therapeutics Product Models, Descriptions and Specifications

Table 113. Aerami Therapeutics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 114. Aerami Therapeutics Recent Developments

Table 115. Medtronic Corporation Information

Table 116. Medtronic Description and Major Businesses

Table 117. Medtronic Product Models, Descriptions and Specifications

Table 118. Medtronic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 119. Medtronic Recent Developments

Table 120. Verily Life Sciences Corporation Information

Table 121. Verily Life Sciences Description and Major Businesses

Table 122. Verily Life Sciences Product Models, Descriptions and Specifications

Table 123. Verily Life Sciences Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 124. Verily Life Sciences Recent Developments

Table 125. Larimar Therapeutics Corporation Information

Table 126. Larimar Therapeutics Description and Major Businesses

Table 127. Larimar Therapeutics Product Models, Descriptions and Specifications

Table 128. Larimar Therapeutics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 129. Larimar Therapeutics Recent Developments

Table 130. Senseonics Corporation Information

Table 131. Senseonics Description and Major Businesses

Table 132. Senseonics Product Models, Descriptions and Specifications

Table 133. Senseonics Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 134. Senseonics Recent Developments

Table 135. Bigfoot Biomedical Corporation Information

Table 136. Bigfoot Biomedical Description and Major Businesses

Table 137. Bigfoot Biomedical Product Models, Descriptions and Specifications

Table 138. Bigfoot Biomedical Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 139. Bigfoot Biomedical Recent Developments

Table 140. Key Raw Materials Distribution

Table 141. Raw Materials Key Suppliers

Table 142. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 143. Milestones in Production Technology Evolution

Table 144. Distributors List

Table 145. Market Trends and Market Evolution

Table 146. Market Drivers and Opportunities

Table 147. Market Challenges, Risks, and Restraints

Table 148. Research Programs/Design for This Report

Table 149. Key Data Information from Secondary Sources

Table 150. Key Data Information from Primary Sources

List of Figures

Figure 1. Non-injectable Insulin Product Picture

Figure 2. Global Non-injectable Insulin Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Oral Pills Product Picture

Figure 4. Sprays Product Picture

Figure 5. Others Product Picture

Figure 6. Global Non-injectable Insulin Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 7. T1DM

Figure 8. T2DM

Figure 9. Non-injectable Insulin Report Years Considered

Figure 10. Global Non-injectable Insulin Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 12. Global Non-injectable Insulin Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Non-injectable Insulin Revenue Market Share by Region (2020-2031)

Figure 14. Global Non-injectable Insulin Sales (2020-2031) & (Units)

Figure 15. Global Non-injectable Insulin Sales (CAGR) by Region (2020-2031) (Units)

Figure 16. Global Non-injectable Insulin Sales Market Share by Region (2020-2031)

Figure 17. Top 5 and Top 10 Manufacturers Non-injectable Insulin Sales Volume Market Share in 2024

Figure 18. Global Non-injectable Insulin Revenue Market Share Ranking (2024)

Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 20. Oral Pills Revenue Market Share by Manufacturer in 2024

Figure 21. Sprays Revenue Market Share by Manufacturer in 2024

Figure 22. Others Revenue Market Share by Manufacturer in 2024

Figure 23. Global Non-injectable Insulin Sales Market Share by Type (2020-2031)

Figure 24. Global Non-injectable Insulin Revenue Market Share by Type (2020-2031)

Figure 25. Global Non-injectable Insulin Sales Market Share by Application (2020-2031)

Figure 26. Global Non-injectable Insulin Revenue Market Share by Application (2020-2031)

Figure 27. North America Non-injectable Insulin Sales YoY (2020-2031) & (Units)

Figure 28. North America Non-injectable Insulin Revenue YoY (2020-2031) & (US$ Million)

Figure 29. North America Top 5 Manufacturers Non-injectable Insulin Sales Revenue (US$ Million) in 2024

Figure 30. North America Non-injectable Insulin Sales Volume (Units) by Type (2020- 2031)

Figure 31. North America Non-injectable Insulin Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 32. North America Non-injectable Insulin Sales Volume (Units) by Application (2020-2031)

Figure 33. North America Non-injectable Insulin Sales Revenue (US$ Million) by Application (2020-2031)

Figure 34. US Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 35. Canada Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 36. Mexico Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 37. Europe Non-injectable Insulin Sales YoY (2020-2031) & (Units)

Figure 38. Europe Non-injectable Insulin Revenue YoY (2020-2031) & (US$ Million)

Figure 39. Europe Top 5 Manufacturers Non-injectable Insulin Sales Revenue (US$ Million) in 2024

Figure 40. Europe Non-injectable Insulin Sales Volume (Units) by Type (2020-2031)

Figure 41. Europe Non-injectable Insulin Sales Revenue (US$ Million) by Type (2020-2031)

Figure 42. Europe Non-injectable Insulin Sales Volume (Units) by Application (2020-2031)

Figure 43. Europe Non-injectable Insulin Sales Revenue (US$ Million) by Application (2020-2031)

Figure 44. Germany Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 45. France Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 46. U.K. Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 47. Italy Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 48. Russia Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 49. Asia-Pacific Non-injectable Insulin Sales YoY (2020-2031) & (Units)

Figure 50. Asia-Pacific Non-injectable Insulin Revenue YoY (2020-2031) & (US$ Million)

Figure 51. Asia-Pacific Top 8 Manufacturers Non-injectable Insulin Sales Revenue (US$ Million) in 2024

Figure 52. Asia-Pacific Non-injectable Insulin Sales Volume (Units) by Type (2020- 2031)

Figure 53. Asia-Pacific Non-injectable Insulin Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 54. Asia-Pacific Non-injectable Insulin Sales Volume (Units) by Application (2020-2031)

Figure 55. Asia-Pacific Non-injectable Insulin Sales Revenue (US$ Million) by Application (2020-2031)

Figure 56. Indonesia Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 57. Japan Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 58. South Korea Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 59. China Taiwan Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 60. India Non-injectable Insulin Revenue (2020-2031) & (US$ Million)

Figure 61. Central and South America Non-injectable Insulin Sales YoY (2020-2031) & (Units)

Figure 62. Central and South America Non-injectable Insulin Revenue YoY (2020-2031) & (US$ Million)

Figure 63. Central and South America Top 5 Manufacturers Non-injectable Insulin Sales Revenue (US$ Million) in 2024

Figure 64. Central and South America Non-injectable Insulin Sales Volume (Units) by Type (2021-2031)

Figure 65. Central and South America Non-injectable Insulin Sales Revenue (US$ Million) by Type (2020-2031)

Figure 66. Central and South America Non-injectable Insulin Sales Volume (Units) by Application (2020-2031)

Figure 67. Central and South America Non-injectable Insulin Sales Revenue (US$ Million) by Application (2020-2031)

Figure 68. Brazil Non-injectable Insulin Revenue (2020-2025) & (US$ Million)

Figure 69. Argentina Non-injectable Insulin Revenue (2020-2025) & (US$ Million)

Figure 70. Middle East, and Africa Non-injectable Insulin Sales YoY (2020-2031) & (Units)

Figure 71. Middle East and Africa Non-injectable Insulin Revenue YoY (2020-2031) & (US$ Million)

Figure 72. Middle East and Africa Top 5 Manufacturers Non-injectable Insulin Sales Revenue (US$ Million) in 2024

Figure 73. Middle East and Africa Non-injectable Insulin Sales Volume (Units) by Type (2021-2031)

Figure 74. South America Non-injectable Insulin Sales Revenue (US$ Million) by Type (2020-2031)

Figure 75. Middle East and Africa Non-injectable Insulin Sales Volume (Units) by Application (2020-2031)

Figure 76. Middle East and Africa Non-injectable Insulin Sales Revenue (US$ Million) by Application (2020-2031)

Figure 77. GCC Countries Non-injectable Insulin Revenue (2020-2025) & (US$ Million)

Figure 78. Turkey Non-injectable Insulin Revenue (2020-2025) & (US$ Million)

Figure 79. Egypt Non-injectable Insulin Revenue (2020-2025) & (US$ Million)

Figure 80. South Africa Non-injectable Insulin Revenue (2020-2025) & (US$ Million)

Figure 81. Non-injectable Insulin Industry Chain Mapping

Figure 82. Regional Non-injectable Insulin Manufacturing Base Distribution (%)

Figure 83. Global Non-injectable Insulin Production Market Share by Region (2020-2031)

Figure 84. Non-injectable Insulin Production Process

Figure 85. Regional Non-injectable Insulin Production Cost Structure

Figure 86. Channels of Distribution (Direct Vs Distribution)

Figure 87. Bottom-up and Top-down Approaches for This Report

Figure 88. Data Triangulation

Figure 89. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions